Contribution of constrictor prostanoids to the calcium-dependent basal tone in the aorta from rats with aortic coarctation-induced hypertension: relationship to nitric oxide.

Rings of thoracic aortae taken from rats made hypertensive by aortic coarctation express a calcium-dependent basal tone. We investigated whether this basal tone is mediated by prostanoids. To this end, we contrasted the effects of indomethacin, an inhibitor of cyclooxygenase, and of ifetroban, an antagonist of thromboxane A2/prostaglandin endoperoxide H2 receptors, on basal tone in aortic rings taken from normotensive and hypertensive rats. Rings with endothelium from normotensive rats were unaffected by indomethacin and ifetroban. However, in endothelium-intact rings from hypertensive rats, the basal tone was reduced 65 to 75% by indomethacin and ifetroban, but not by CGS13080, an inhibitor of thromboxane synthase. The reductions in tone elicited by indomethacin and ifetroban in rings from hypertensive rats were eliminated upon removal of the endothelium and were attenuated when the rings were pretreated with an inhibitor of nitric oxide synthase (N omega-nitro-L-arginine methyl ester or N omega-nitro-L-arginine) or an inhibitor of soluble guanylate cyclase. Neither indomethacin nor ifetroban affected tissue cGMP levels or nitrite release in aortic rings taken from hypertensive rats. However, sodium nitroprusside offset the inhibitory effects of N omega-nitro-L-arginine methyl ester, on the relaxant responses to indomethacin and ifetroban. These data suggest that a constrictor prostanoid other than thromboxane A2, presumably prostaglandin endoperoxide H2 contributes to the implementation of the basal tone in rings from hypertensive rats and that part of the relaxant response to indomethacin and ifetroban is linked to nitric oxide.

Heme oxygenase substrates acutely lower blood pressure in hypertensive rats.

Heme oxygenase catalyzes the metabolism of heme to biliverdine, free iron, and carbon monoxide. The current study was designed to determine if treatment with the heme oxygenase substrates heme-L-arginate or heme-L-lysinate, to stimulate formation of heme oxygenase products, can lower blood pressure in the rat. Heme-L-arginate (45 mumol/kg ip) and heme-L-lysinate (45 mumol/kg ip) acutely lowered blood pressure in awake spontaneously hypertensive rats (SHR) by approximately 35 mmHg. For both heme oxygenase substrates, this effect was blunted by pretreatment with an inhibitor of heme oxygenase, zinc deuteroporphyrin 2,4-bis glycol. Heme-L-lysinate also lowered arterial pressure in deoxycorticosterone acetate-salt hypertensive rats and in rats with phenylephrine-induced hypertension, indicating that the vasodepressive actions of heme may be extended to other hypertensive models. However, neither heme-L-arginate nor heme-L-lysinate decreased blood pressure in normotensive controls. The heme oxygenase product biliverdine did not lower blood pressure in SHR, and the vasodepressive actions of heme-L-lysinate were unaffected by pretreatment with deferoxamine to chelate free iron. Carbon monoxide (12 ml/kg ip) lowered blood pressure in SHR and in rats made hypertensive by phenylephrine infusion, had no effect on blood pressure in Wistar-Kyoto rats, and elicited only a modest vasodepressive response in normotensive Sprague-Dawley rats. We conclude that heme-bearing preparations can lower blood pressure in hypertensive rats, presumably via heme oxygenase-mediated formation of carbon monoxide.